The australia nuclear imaging market size is expected to grow from USD 185.68 million in 2025 to USD 201.33 million in 2026 and is forecast to reach USD 301.78 million by 2031 at 8.44% CAGR over 2026-2031. This report is Segmented by Product (Equipment, Radioisotope Including SPECT Radioisotopes and PET Radioisotopes), Application (Cardiology, Neurology, Thyroid, Oncology, Other Applications), End User (Hospitals, Diagnostic Imaging Centres, Academic & Research Institutes), and Geography. The Market Forecasts are Provided in Terms of Value (USD Million).
Innovation in compact cyclotrons and decentralized generator systems opens new addressable pockets in regional Australia. Foreign OEMs like Siemens Healthineers maintain share through bundled service contracts, yet rising sovereign capability in detector manufacturing is gradually diversifying the supply base. The combination of equipment leadership and isotope growth sustains a balanced revenue mix within the Australia nuclear imaging market.
Australia Nuclear Imaging Market Trends and Insights
Growing Oncology PET-CT Demand
Cancer prevalence and evolving treatment algorithms continue to lift procedure volumes, with ANSTO facilitating 10,000-12,000 nuclear medicine studies every week. The recent FDA nod for Telix’s Gozellix PSMA agent intensifies focus on precision prostate imaging. Integration of theranostic protocols, highlighted by Lutetium-177 PSMA-617 trials at Peter MacCallum Cancer Centre, cements demand for high-end PET-CT scanners. Hospitals are expanding cyclotron access to ensure F-18 FDG availability, reducing delivery risk across state borders. As oncology shifts toward individualized therapy, PET-CT capacity becomes a strategic differentiator within the Australia nuclear imaging market.Increasing Public-Hospital SPECT Upgrades
Medicare guidelines that cap scanner lifespan at 10 years trigger predictable replacement waves. State procurement clusters combine volumes to negotiate favorable pricing, accelerating adoption of AI-ready SPECT technology. Upgraded systems lower radiopharmaceutical dose and shrink scan times, allowing departments to accommodate rising referrals despite specialist shortages. The mandatory coverage rule - where outdated units lose MBS eligibility - pressures administrators to modernize and sustains revenue visibility for vendors across the Australia nuclear imaging market.Mo-99 Global Supply-Chain Fragility
The February 2023 safety incident at Lucas Heights temporarily halted domestic Mo-99 output and forced emergency imports, prompting schedule backlogs nationwide. Because Mo-99 decays within 66 hours, even brief outages jeopardize cardiac imaging services that rely on 99mTc generators. Domestic reliance on a single reactor remains a structural risk until cyclotron-based alternatives or LEU-fueled reactors scale commercially. Contingency stockpiling is limited, making consistent isotope access a fragile linchpin for the Australia nuclear imaging market.Other drivers and restraints analyzed in the detailed report include:
- Expansion of Cyclotron-Based F-18 Supply
- Federal Funding for Theranostics Centres
- Capital-Equipment Budget Constraints
Segment Analysis
Equipment captured 63.42% of 2025 revenue as hospitals refreshed legacy SPECT cameras and added high-end digital PET-CT units. GE HealthCare’s rollout of total-body scanners at Peter MacCallum Cancer Centre exemplifies migration toward ultra-low-dose platforms. The Australia nuclear imaging market size for radioisotopes, though smaller today, is expanding swiftly on an 8.78% CAGR trajectory through 2031, propelled by theranostic isotopes such as Cu-64 and Ac-225. Domestic suppliers benefit from ANSTO’s GenTech 99mTc generators, while Clarity Pharmaceuticals’ copper-based pipeline adds competitive depth.Innovation in compact cyclotrons and decentralized generator systems opens new addressable pockets in regional Australia. Foreign OEMs like Siemens Healthineers maintain share through bundled service contracts, yet rising sovereign capability in detector manufacturing is gradually diversifying the supply base. The combination of equipment leadership and isotope growth sustains a balanced revenue mix within the Australia nuclear imaging market.
Complete Report Scope:
- By Product
- Equipment
- Radioisotope
- SPECT Radioisotopes
- Technetium-99m (TC-99m)
- Thallium-201 (TI-201)
- Gallium (Ga-67)
- Iodine (I-123)
- Other SPECT Radioisotopes
- PET Radioisotopes
- Fluorine-18 (F-18)
- Rubidium-82 (RB-82)
- Other PET Radioisotopes
- SPECT Radioisotopes
- By Application
- Cardiology
- Neurology
- Thyroid
- Oncology
- Other Applications
- By End User (Value)
- Hospitals
- Diagnostic Imaging Centres
- Academic & Research Institutes
List of Companies Covered in this Report:
- Siemens Healthineers
- GE HealthCare Technologies Inc.
- Royal Philips N.V.
- Canon
- United Imaging Healthcare Co., Ltd.
- Telix Pharmaceuticals Limited
- Clarity Pharmaceuticals Ltd
- Australian Nuclear Science and Technology Organisation (ANSTO)
- Cyclotek Pty Ltd
- Sirtex Medical Limited
- Eckert & Ziegler AG
- Jubilant Pharma Limited
- Radiopharm Theranostics Ltd
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
Table of Contents
1 Introduction
4 Market Landscape
5 Market Size & Growth Forecasts (Value, USD Million)
6 Competitive Landscape
7 Market Opportunities & Future Outlook
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Siemens Healthineers AG
- GE HealthCare Technologies Inc.
- Royal Philips N.V.
- Canon Medical Systems Corporation
- United Imaging Healthcare Co., Ltd.
- Telix Pharmaceuticals Limited
- Clarity Pharmaceuticals Ltd
- Australian Nuclear Science and Technology Organisation (ANSTO)
- Cyclotek Pty Ltd
- Sirtex Medical Limited
- Eckert & Ziegler AG
- Jubilant Pharma Limited
- Radiopharm Theranostics Ltd
